Tanja Novakovic


Tanja Novakovic MSc Pharm is the president of the Pharmacoeconomics Section within the Pharmaceutical Association of Serbia (from 2006 - to date). She is a founder of the ISPOR Serbian chapter and between 2007 and 2009 its vice president. Tanja Novakovic is a graduate of the University of Belgrade, Faculty of Pharmacy finishing her postgraduate studies at the Faculty of Pharmacy at Ghent University in Belgium. She is employed at Galenika as product manager for CNS drugs.

She is the author of the “Handbook for pharmacoeconomic evaluations”, the first such publication in the Serbian language. She was active in shaping healthcare policy, writing the first Guidelines for pharmacoeconomic evaluations for Serbia. She was also co-author in one of the three HTA reports first completed in Serbia, and was engaged to lead a group of experts to define all existing elements of basic benefit package in Serbia within the World Bank/Ministry of Health of Serbia projects. Tanja participated in several projects in different fields: big data, disease areas such as oncology, rare diseases, nutrition, rheumatogy, biosimilars etc. Tanja has organized and presented in many national meetings and international conferences which have resulted in international cooperation in education and the developing of pharmacoeconomics and HTA in Serbia and the region.




Alessandra Ferrario


Alessandra Ferrario has recently completed her PhD at the London School of Economics (March 2017) and will start her postdoc at Harvard Medical School in July 2017 on the intensity of end-of-life care in breast cancer patients. She has been working as a Research Officer at LSE from 2011-2017 on pharmaceutical policy issues and non-communicable diseases. Alessandra’s PhD investigated issues around access to new cancer medicines in Europe. In particular, cross-country variations in access, the use of risk-sharing and managed entry agreements and strategic procurement. Alessandra has worked with the World Health Organization on pricing and procurement at global and European level and on availability, affordability and quality use of medicines in Estonia, the Republic of Moldova and Tajikistan. She holds an MSc in Health Policy, Planning and Financing (LSE/LSHTM), MSc in Epidemiology (Swiss Tropical and Public Health Institute, University of Basel) and BSc in Molecular Biology (University of Basel).




Bojan Trkulja


Bojan Trkulja is managing director of INOVIA (Association of Innovative Drug Manufacturers in Belgrade, Serbia). He was born in 1971 in Belgrade, where he completed his elementary, high school and medical university. After a successful internship and passing the state exam, he worked in the office of F. Hoffmann – La Roche in Belgrade, from December 1999. Over the last 11 years he held a variety of positions, from associate through the Medical Product Manager, Compliance Officer and Market Access Manager.


Krzysztof Landa


Krzysztof Landa is the Board Member of the National Center of Research & Development (NCBiR) of Republic of Poland.  Dr Landa held the position of Deputy Minister of Health of Republic of Poland for last two years. He is The Founder of Watch Health Care Foundation ( The CEO of MedInvest Scanner Ltd. General partner in HTA Audit, a company dealing with quality of HTA (Health Technology Assessment) reports directed to authorities and public institutions in Poland; expert of BCC on health care system. From 2010 till 2011 he was President of Central & Eastern European Society of Technology Assessment in Health Care. In 2006-2007 Dr Landa was the Director of Drug Policy Department in the Central Office of National Health Fund. In 2004 Krzysztof Landa was elected to the Board of Directors of Health Technology Assessment International (HTAi) and performed his duties till mid-2007. He was the Chairman of the LOC of the first HTAi Annual Meeting 2004, held in Krakow, Poland. Dr Landa is a graduate of the University School of Medicine and received his management education at the Postgraduate School of Public Health of Jagiellonian University in Krakow. Promotion of HTA in the region of CEE resulted in international cooperation in education and HTA. Dr Landa organized many national and international HTA workshops and conferences. In years 2006 – 2008 Dr Landa provided consultancy for the Serbian Ministry of Health. He was team leader of the World Bank project aimed at introduction of HTA in Serbia, implementation of EBHC principles to the management of basic benefit package and designing a governmental HTA Agency.



Magdalena Wladysiuk


Magdalena Wladysiuk is the Vice President of HTA Consulting, President of CEESTAHC Society. In HTA Consulting, she is responsible for the strategic development of the company through research and services development, new product launch and marketing. Ms. Wladysiuk main and primary aim is to provide high quality information or data based on evidence based medicine or health technology assessment methodology not only in Poland but in Europe and Asia. Key role of her work is to improve patient outcomes through better healthcare decisions. HTA Consulting provides wide scope of service to planning, collecting, analyzing and presenting clinical, cost data, health technology assessment report to public and private sector - healthcare professionals, payers, hospitals, and employers.

In CEESTAHC she was responsible for the establishing and providing wide connection platform for discussion for all stakeholders in health care system. CEESTAHC mission is to improve the quality of health care systems value with the use of evidence.


·   Graduate of the Medical Academy in Lublin in 2000

·   MBA and economy in Kozminski Academy in Warsaw in 2004

·   Founder of the CEESTAHC in 2003 and its President up to 2005 and from 2010 again

the President of CEESTAHC

·   Member of HTAi Annual Meeting in 2006-2008

·   Ph.D. Program from 2011 in Medical Academy in Lublin

Jaroslav Duba


Jaroslav Duba is owner and CEO at OAKS Consulting s.r.o. Jaroslav founded OAKS Consulting s.r.o. in 2009, after more then 15 years of experience in top management positions in Wyeth, Zentiva and Glaxo. OAKS Consulting has became in short time the leading consulting company providing full scope of services in MARKET ACCESS in Czech Republic. The team currently consists of 15 specialists with professional background in medicine, pharmacology, mathematical modeling and health-economy.

David Danko


Dávid Dankó is managing partner of Ideas & Solutions (I&S), an independent research and consultancy firm which provides health policy and market access advisory services to pharma and medical device companies with a focus on emerging and middle-income markets. He also holds a position as research leader at the Corvinus University of Budapest, Hungary, where he lectures pharmaceutical policy and funding.


Dávid has 14 years of experience in health care management & the funding of pharmaceuticals and medical devices. Until 2010 he was member of the executive team for pharmaceutical reform in Hungary as deputy director of reimbursement at the national health insurance fund. He speaks regularly at conferences and workshops on pharmaceutical and medical device policies, gives payer communication and negotiation trainings to multinational companies and authorities.



·   Pragmatic value assessment and HTA systems for middle-income markets

·   Process and data transparency of pharmaceutical decision-making processes

·   Linking managed entry agreements to value assessment of pharmaceuticals

·   Negotiations and communication with payers and other governmental stakeholders

·   Alternative funding strategies for middle and low-income countries


Dávid has lectured at the European Market Access University Diploma (EMAUD) programme, the Semmelweis University of Budapest, Debrecen University, Eötvös Loránd University and the former Vienna School of Clinical Research. He graduated in Economics from Corvinus University of Budapest and earned a PhD degree in 2012 with his thesis on resource management in pharmaceutical research & development.


Dávid is peer-reviewer and editorial board member of three health economics and market access journals. He is also co-editor of a university textbook titled ‘Pharmaceutical Reimbursement’ and co-author of the Pharmacoeconomics and Outcomes Research Guidelines for India.


Simo Vukovic


Simo Vukovic is coordinator of the Component Improvement of Health Financing of the Second Serbia Health Project. Dr. Vukovic is a Specialist Doctor of Gynecology and Obstetrics, and he obtained a PhD title in Health Management from the European Center for Peace and Development of UN University for Peace. He started his professional engagement in the Clinical Center of Serbia, continuing his work as Assistant Professor in the European Center for Peace and Development, and later as the Director of International ECPD Summer School of Management in Healthcare Institutions and the founder of the clinic Vanna Care. He has been a member of the Serbian Medical Chamber since 2008, and he gained significant professional experience at the positions of Advisor to the Minister of health of Montenegro, MP in the National Parliament of Serbia, member of City Council of the City of Belgrade, President of Managing Board of the Clinical Center of Serbia and State Secretary in the Ministry of Health. He is the founder of non-government organization Health Monitor. He is the winner of NALED's Top Reformer award for 2013, now acting as NALED-s expert consultant for healthcare.


Nikos Kotsopoulos


Nikos Kotsopoulos is a health economist with 15 years of experience in the pharmaceutical industry and related consulting. Nikos has held global and regional positions for the pharmaceutical industry and has conducted several health economic studies in both developed and developing countries. He also is a guest lecturer at the University of Athens, School of Public Policy and Administration. In recent years Nikos has contributed to the development of a novel analytic framework that assesses the macroeconomic and fiscal effect of investments in healthcare. The analytic framework developed by Nikos and his team has been incorporated into the WHO framework on broader impact of vaccination to inform decision-makers. Nikos is a partner at Global Market Access Solutions, with licensed offices in Switzerland, UK and US. He has received formal post-graduate training in health economics at the University of Groningen (PhD), and City University, London (MSc).



Antony P. Martin


Antony P. Martin is Research Fellow in Health Economics at Liverpool Health Economics. Since joining LHE, Antony has made significant contributions towards several innovative projects. He completed his BSc in Economics at the University of Liverpool and his MSc in Health Economics at City University London, funded by a scholarship from the NIHR. Previously, he worked for a leading health economics and outcomes research consultancy company, gaining experience in cost-effectiveness model adaptations, budget impact models, systematic literature reviews and health technology assessment reports. Antony is undertaking a PhD to examine the clinical and cost-effectiveness of pharmacogenetic tests. In addition, he is looking to explore issues surrounding equity in the delivery of personalized healthcare. Antony has experience working within a range of health areas such as alcoholism, hepatitis C, HIV/AIDS, pre-term birth, and he has developed a keen interest in health policy debate. He has also developed an international profile after spending extended periods of time studying and working abroad in Brazil, Hong Kong and Peru.

Session SFE SFUS - 7th Serbian Congress of Pharmacy
Friday 12th October 2018, Crowne Plaza Hotel, Belgrade, Serbia
Is Belgrade the New Berlin?
APRIL 6, 2017
No city makes you feel more like a New Yorker than Belgrade. In Belgrade, people don’t walk, they amble; lunch spans the course of 3 or 4 hours; and drinks are sipped, never knocked back. Despite the slow pace of life, there’s still an unmistakable energy that bursts through the city.
Preliminary Program

The preliminary program for the conference "THE VALUE OF INNOVATION IN DECISION MAKING" is now available. Use the link above or access from the menu in the top right.
VI International SFE SFUS Conference
2nd June 2017, Belgrade, hotel Metropol, Serbia.

The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia (SFE SFUS) is organising its Sixth International Conference with the topic:
Fifth International Conference - Speakers
9th and 10th of October 2015 Belgrade, hotel Metropol
Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden

Wija Oortwijn PhD, Partner at ECORYS NL, The Netherlands

Krzysztof Landa MD, President at MedInvest Scanner Ltd M.I.S., Poland

Mark Parker MSc, Health Economics Unit, University of Liverpool Management School, UK

Angela Yu MSc, London School of Economics, UK

Timothy Johnston, Program Leader for Inclusive Growth and Human Development, Southeast Europe, Europe and Central Asia Region, World Bank

Dávid Dankó PhD, Managing Director at Ideas & Solutions, Hungary

Dr. Günter Harms, Market Access and Public Affairs Director, Shire, Germany

Vanesa Benkovic MSc, Senior HTA and health research consultant, Croatia

Bojan Trkulja MD, Managing Director at INOVIA, Serbia

Tanja Novakovic MSc Pharm, President of Pharmacoeconomics Section, Serbia, Representative of Chamber of Commerce and Industry of Serbia

Jovan Mihajlovic, MSc Pharm, Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands

Livio Garattini, Mario Negri Institute, Milano, Italija

Jakub Adamski, Arcana Institute, Poland

Alan Haycox, MSc, Health Economics Unit, University of Liverpool Management School, UK

Norbert Wilk, Arcana Institute, Poland

Neven Lovrinov, MSc Pharm, Terminal d.o.o., Croatia

Belgrade, 28th April 2015, hotel Crowne Plaza
The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia
The objectives of the conference are:

• present the characteristics of biopharmaceutical medicines and biosimilars,

• understanding the nature of biopharmaceutical and biosimilar regulations,

• share clinical experience with biological medications and more generally

• exchanging experiences and knowledge with experts from the region and international stage.
Managed Introduction of new medicines
11 – 13 May 2015 - Warsaw, Poland
PIPERSKA workshop co-organised with the Agency for HTA & Tariff System in Poland and WHO Europe
This course is primarily intended for healthcare
professionals involved with enhancing the rational use
of medicines especially new medicines
Fifth Adriatic and Fourth Croatian Congress of Pharmacoeconomics and Outcomes Research
Šibenik, Croatia, from 23rd to 26th April 2015.
Section for Pharmacoeconomics and Outcomes Research of the Croatian Society for Clinical Pharmacology and Therapeutics, Croatian Medical Association
This year focus will be on the following subjects: 'The role and impact of pharmaceutical industry on the general economy in countries in the region' and 'The need to adapt the model for health technology assessment in countries with high risk of sustainability of healthcare financing in order to ensure transparency and competitiveness'.
5th of February 2015 Crowne Plaza Hotel, Belgrade, SERBIA
SFUS Pharmacoeconomics Section
The purpose of the Conference is to:
• Introduce and present the importance and value of patient registries,
• Introduce health outcomes and treatment outcomes reported by patients,
• Exchange experiences across the countries that used data of patients registers in the
pharmacoeconomic analysis
• Introduce the examples of special agreements (Risk sharing, Pay per Performance)
HTA for Healthcare Quality Assurance
December 15th-16th, 2014, Kraków, Poland
CEESTAHC 9th International Symposium Evidence-Based Health Care 2014